Clinical Trial: Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease
Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Randomized Control Trial of Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease
Brief Summary: Active vitamin D at therapeutic dose may prevent vascular calcification but in supraphysiologic dose may precipitate it.
Detailed Summary: Active vitamin D compound is used frequently in the treatment of hyperparathyroidism in chronic kidney disease. Recent evidence from animal studies suggested that low dose of active vitamin D may be protective against vascular calcification, whereas high dose could precipitate it. The present study will examine the effect of low dose oral alfacalcidol on coronary artery calcification in predialysis chronic kidney disease patients with hyperparathyroidism.
Sponsor: Ramathibodi Hospital
Current Primary Outcome: Change in Coronary Artery Calcification [ Time Frame: 6 months and 12 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Ramathibodi Hospital
Dates:
Date Received: May 26, 2011
Date Started: May 2011
Date Completion: December 2012
Last Updated: May 31, 2011
Last Verified: May 2011